This website uses cookies to enhance the user experience.
FM

Frode Marc Bohan1968

Shareholdings
2
25
Norway Business roles
0

Roles

No available data

Related industries

No related industries

Direct relationships

No direct relationships

Shares owned by Frode Marc Bohan

NameShare classTotal operating incomeTotal equityShare
B
BOHAN & CO AS
Ordinære aksjer
6,874,227
178,144,452
100 %
directly
F
FK INVESTMENT AS
0
-4,898,205
50 %
indirectly
S
SMARTFISH AS
17,077,930
-450,548
35.45 %
indirectly
N
NATTOPHARMA AS
29,582,426
26,291,781
35.45 %
indirectly
N
NORDIC HEALTHY LIVING AS
25,445,079
31,114,761
35.45 %
indirectly
I
IP EQOLOGY HOLDCO AS
0
33,213,514
35.45 %
indirectly
I
IMMUNOPHARMA AS
14,110,340
195,301,042
35.45 %
indirectly
M
MYCOTECH PHARMA AS
2,033,410
15,069,392
35.34 %
indirectly
E
EQOLOGY AS
1,742,200
46,583,991
35.08 %
indirectly
Q
QI PROPERTY AS
942,750
-2,233,045
13.05 %
indirectly
V
VISUADO AS
3,039,031
17,642,978
13.05 %
indirectly
B
BLUE HELIX HEALTH AS
Ordinære aksjer
118,500
-2,227,524
2.67 %
directly 2.67 %
indirectly 86.42 %
N
NORBECO AS
593,030
-583,447
1.22 %
indirectly
B
BRAGERNES TORG 12 AS
8,249,394
73,795,025
0.88 %
indirectly
A
AVA EIENDOMSFORVALTNING AS
15,649,097
7,093,500
0.88 %
indirectly
A
AVA EIENDOMSPARTNER AS
0
1,277,573,133
0.88 %
indirectly
E
ELVEGATEN EIENDOM INVEST AS
22,317,240
75,682,715
0.88 %
indirectly
B
BRAGERNES TORG 10 AS
1,832,667
447,812
0.88 %
indirectly
B
BRAGERNES PARKERING AS
2,144,629
373,447
0.88 %
indirectly
B
BRAGERNES TORG 8 AS
5,036,875
5,985,465
0.88 %
indirectly
A
AVA EIENDOM AS
0
505,245,368
0.88 %
indirectly
A
AMTMAND BLOMS GATE 1 AS
2,808,856
6,386,977
0.88 %
indirectly
S
SANDVIKA EIENDOM AS
2,715,545
9,571,488
0.88 %
indirectly
V
VICTORIAGÅRDEN HANDEL AS
3,181,446
10,314,086
0.88 %
indirectly
V
VICTORIAGÅRDEN KONTOR AS
5,780,618
9,957,855
0.88 %
indirectly
B
BRAGERNES TORG 1 AS
392,978
-696,093
0.88 %
indirectly
K
KIRKEGATA 23-25 HOLDING AS
0
488,772,093
0.57 %
indirectly

Limited to direct ownership positions of 0.5% or more.

Last update: Jun 2, 2025